Brokerages forecast that Chimerix, Inc. (NASDAQ:CMRX) will announce earnings of ($0.43) per share for the current quarter, according to Zacks. Three analysts have issued estimates for Chimerix’s earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.39). Chimerix posted earnings per share of ($0.37) during the same quarter last year, which suggests a negative year over year growth rate of 16.2%. The business is expected to report its next quarterly earnings report on Monday, November 6th.

According to Zacks, analysts expect that Chimerix will report full year earnings of ($1.68) per share for the current financial year, with EPS estimates ranging from ($1.87) to ($1.57). For the next year, analysts expect that the company will post earnings of ($1.85) per share, with EPS estimates ranging from ($2.18) to ($1.49). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Chimerix.

Chimerix (NASDAQ:CMRX) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.05. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%.

Several research firms recently weighed in on CMRX. Zacks Investment Research downgraded Chimerix from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. ValuEngine downgraded Chimerix from a “hold” rating to a “sell” rating in a report on Friday, August 11th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Teachers Advisors LLC boosted its holdings in shares of Chimerix by 0.3% during the 4th quarter. Teachers Advisors LLC now owns 69,888 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 204 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Chimerix by 3.8% during the 1st quarter. Bank of Montreal Can now owns 39,300 shares of the biopharmaceutical company’s stock valued at $251,000 after acquiring an additional 1,448 shares in the last quarter. American International Group Inc. boosted its holdings in shares of Chimerix by 7.1% during the 1st quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock valued at $168,000 after acquiring an additional 1,733 shares in the last quarter. Nationwide Fund Advisors boosted its holdings in shares of Chimerix by 5.9% during the 1st quarter. Nationwide Fund Advisors now owns 35,573 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 1,977 shares in the last quarter. Finally, Alps Advisors Inc. boosted its holdings in shares of Chimerix by 5.5% during the 2nd quarter. Alps Advisors Inc. now owns 42,023 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 2,178 shares in the last quarter. 67.53% of the stock is currently owned by institutional investors.

Chimerix (CMRX) traded up 0.20% during midday trading on Friday, hitting $5.06. The stock had a trading volume of 56,548 shares. The company’s market capitalization is $238.05 million. The company’s 50-day moving average price is $4.72 and its 200 day moving average price is $5.30. Chimerix has a 52 week low of $3.66 and a 52 week high of $6.64.

COPYRIGHT VIOLATION NOTICE: “Chimerix, Inc. (CMRX) Expected to Post Earnings of -$0.43 Per Share” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/13/chimerix-inc-cmrx-expected-to-post-earnings-of-0-43-per-share.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.